This site uses cookies. By using this site you agree to receiving cookies. View Policy.

167%
Raised
£836,370
Investors
862
Target
£500,000
Equity
8.29%
Pre-money valuation
£9,250,000

Cell Guidance Systems is developing a patented technology to unlock the medical potential of growth factor proteins. PODS enables proteins to treat diseases, such as Parkinson's disease and osteoarthritis, by improving their delivery to the disease site. The technology addresses multi-$bn markets.

  • Unique patented technology proven in animal models of disease
  • Aiming to address multiple global healthcare issues affecting millions
  • Working with University of Cambridge on lead osteoarthritis programme
  • Medical research reagent division, generating >£1m in revenues in 2017
Information Due to ongoing overfunding momentum, the pitch has been extended and will now expire at midnight on Friday 1st June 2018.

Idea

Most of the world's top-selling drugs are proteins. Humira alone generated sales >$18bn in 2017 (www.statista.com).

Cell Guidance Systems, based in Cambridge at the heart of the UK biotech industry, is developing PODS (Polyhedrin Delivery System), a platform technology for sustained growth factor delivery protected by exclusively licensed patents. PODS has the potential to transform medical care for many common diseases including osteoarthritis, neurodegenerative disease (such as Parkinson’s disease and motor neuron disease), wound healing, eye disease, and cancer. PODS research also shows potential for the delivery of vaccines. Our lead programme for osteoarthritis is being developed with the University of Cambridge.

Cell Guidance Systems generated revenues of >£1m in revenue in 2017 when consolidated with revenue from its wholly owned US subsidiary, (operating at a £90k loss). Our objective is to become a leading global therapeutic protein delivery company, with therapeutic products in clinics within 3 years.

Why is delivery important?

Growth factors, a particularly potent class of proteins, guide cells to regenerate damaged tissue, but most need to be targeted by precise surgical delivery to avoid harmful side effects. Since daily surgery isn't practical and growth factors can be slow-acting and fragile, a technology providing sustained release of stabilized protein is required.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

To see the rest of the Cell Guidance Systems pitch, join now. It's free, quick and easy.

Due to financial regulations, you need to join our community to view the full investment opportunity.

Join

Already registered?
Log in

Risk warning

Investments of this nature carry risks to your capital, including illiquidity, lack of dividends and dilution. Balance risk with a diversified portfolio. Read more. Approved as a financial promotion by Crowdcube Capital Limited, which is authorised and regulated by the Financial Conduct Authority.

Investment opportunities are not offers to the public and investors must be eligible Crowdcube members. Further restrictions and Crowdcube's limitation of liability are set out in the Investor Terms and Conditions. Please seek independent advice as required as Crowdcube does not give investment or tax advice.

Cell Guidance Systems has been given advance assurance by HMRC that the proposed share issue is likely to qualify for Enterprise Investment Scheme (EIS) tax relief.

Tax relief is available to individuals only, with income tax relief currently set at 30 per cent of the cost of the shares for the tax year in which the investment was made. The tax reliefs can also reduce your Capital Gains Tax bill. Read More.

Availability of tax relief depends on your individual and the company’s ongoing circumstances and applicable law.